Drug intelligence / Profile preview

Feibi Granule

Development stage: Preclinical
Lead developer: Beijing University of Chinese Medicine Fangshan Hospital
Modality: Small Molecules
Administration: Oral

Overview

Feibi Granule is a Traditional Chinese Medicine (TCM) formulation developed by Fangshan Hospital of the Beijing University of Chinese Medicine. It is primarily investigated for the treatment of coal worker's pneumoconiosis (CWP) in the remission or stable stage. The drug is designed to alleviate clinical symptoms such as dyspnea (shortness of breath), improve lung function, and enhance the overall quality of life for patients suffering from this occupational lung disease. As a TCM granule, it likely consists of a combination of herbal extracts aimed at addressing the underlying pulmonary inflammation and fibrosis associated with chronic lung conditions.

Brand names: Feibi Granule
Other names: Feibi Keli

Beyond the preview

Go deeper on Feibi Granule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Feibi Granule.

Explore the full profile